Compare Campbell Soup Co. (CPB) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs GSK plc — how do they compare? Campbell Soup Co. trades at $22.7 (market cap $6.78B), while GSK plc trades at $50.33 (market cap $102.60B). The key difference: GSK plc is far larger — about 15.1× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (6.87%). Which is the better fit depends on your goals.
| CPB | GSK | |
|---|---|---|
Market Cap | $6.78B | $102.60B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $61.18 |
52-Week Low | $20.00 | $38.22 |
Enterprise Value | $13.38B | $123.04B |
Dividend Yield | 6.87% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.61, up 0.85% with a bullish technical signal. The company shows stable revenue around $10B but faces margin pressure with net income margin at 6.12%. Recent earnings have been mixed with Q2 2026 results pending. Valuation appears reasonable with P/E of 11.14 and P/S of 0.68. The stock offers a dividend yield around 7%, supported by ongoing product innovation including new protein soups and gluten-free options.
CPB presents a value opportunity with attractive dividend yield but faces execution risks amid margin challenges. Analyst consensus remains cautious with 58.6% hold ratings. The key catalyst is successful implementation of cost-saving initiatives and portfolio rebalancing to improve profitability. Near-term performance depends on Q2 earnings results and consumer spending trends.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
